Haleon (HLN) Cash & Equivalents (2021 - 2025)
Haleon (HLN) posted Cash & Equivalents of $1.8 billion for Q4 2025, down 39.02% on a QoQ basis from $2.9 billion in Q4 2024, and down 39.02% year-over-year from $2.9 billion in Q4 2024.
Haleon (HLN) Cash & Equivalents (2021 - 2025) Analysis & Trends
Haleon's Cash & Equivalents history runs 5 years deep, the most recent figure standing at $1.8 billion for Q4 2025.
- Quarterly Cash & Equivalents fell 39.02% year-over-year to $1.8 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.8 billion (down 39.02% YoY) and the FY2025 annual result came in at $1.7 billion, down 39.3% from the prior year.
- Cash & Equivalents was $1.8 billion for Q4 2025 at Haleon, down from $2.9 billion in the prior quarter.
- Across five years, Cash & Equivalents topped out at $2.9 billion in Q4 2024 and bottomed at $558.1 million in Q4 2021.
- A 5-year average of $1.3 billion and a median of $1.0 billion in 2023 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents sank 63.5% — and 2024, when it surged 122.87%.
- Haleon's Cash & Equivalents stood at $558.1 million in 2021, then soared by 43.76% to $802.3 million in 2022, then soared by 61.51% to $1.3 billion in 2023, then jumped by 122.87% to $2.9 billion in 2024, then plunged by 39.02% to $1.8 billion in 2025.
- Business Quant data shows HLN's Cash & Equivalents at $1.8 billion in Q4 2025, $2.9 billion in Q4 2024, and $670.2 million in Q2 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 137.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.76 Bn |
| Dec 31, 2024 | 2.89 Bn |
| Jun 30, 2024 | 670.24 Mn |
| Dec 31, 2023 | 1.30 Bn |
| Jun 30, 2023 | 613.17 Mn |
| Dec 31, 2022 | 802.28 Mn |
| Jun 30, 2022 | 1.68 Bn |
| Dec 31, 2021 | 558.08 Mn |